ClinConnect ClinConnect Logo
Search / Trial NCT05291845

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Launched by ZAGAZIG UNIVERSITY · Mar 14, 2022

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for common warts, which are caused by the Human Papilloma Virus (HPV). Researchers want to find out if a combination of a Candida antigen and a bivalent HPV vaccine can help treat warts more effectively. The trial is currently looking for participants of all genders, aged 32 to 87, who have multiple warts that have not responded well to previous treatments.

If you join the study, you will receive either the new treatment or a combination of treatments, and the researchers will monitor how well it works and if there are any side effects. To be eligible, you should not be pregnant and must not have an allergy to either the Candida antigen or the HPV vaccine. This trial aims to provide a better option for people struggling with persistent warts, and your participation could contribute to important medical knowledge.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study
  • Exclusion Criteria:
  • Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine

About Zagazig University

Zagazig University, a prominent educational and research institution located in Egypt, plays a pivotal role in advancing medical knowledge and promoting health innovations through its clinical trials. With a commitment to excellence in research, the university leverages its diverse expertise and state-of-the-art facilities to conduct rigorous clinical studies that aim to improve patient care and outcomes. By fostering collaboration among multidisciplinary teams, Zagazig University contributes significantly to the global medical community, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements.

Locations

Zagazig, Al Sharqia, Egypt

Patients applied

0 patients applied

Trial Officials

Reham Essam, MD

Principal Investigator

Zagazig University

Ahmad Nofal, MD

Study Director

Zagazig University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials